AkzoNobel ups pharma salt capacity in Denmark

By Dan Stanton

- Last updated on GMT


Related tags Active pharmaceutical ingredient Pharmaceutical drug Pharmacology Denmark

AkzoNobel has expanded a facility in Denmark on the back of high demand for pharmaceutical grade salt.

AkzoNobel’s salts are used as an active pharmaceutical ingredient (API) in a number of applications, including intravenous solutions and insulin, and the 60% increased capacity at its Mariager, Denmark facility will keep up with demand, the firm said.

“Our facility produces the purest salt in the world,”​ said Nils van der Plas, general manager of AkzoNobel’s Salt business. “This expansion will now enable us to serve a strong growing market worldwide.”

Spokesman Andrew Wood was unable to disclose further details on the investment at the site or the total capacity.

Mariager was originally granted US FDA GMP accreditation in March 2006, and EU certification in 2008.

The Mariager facility is dedicated to the production of Sanal, with two quality grades produced on site. Sanal P NaCl pharmaceutical quality is manufactured for use in drug production and is free from bacterial endotoxins and is compliant with GMP-ICH Q7A.

Both of these traits are also applicable to the other quality grade, Sanal SQ, which also meets the American Chemical Society’s (ACS) requirements for highly pure fine chemicals.

Sanal SQ has a NaCl content of over 99.99% as opposed to 99.96% for the pharmaceutical grade. 

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more